重藥控股(000950.SZ):子公司就收購重慶長聖醫藥51%股權的股權轉讓合同生效
格隆匯 1 月 12日丨重藥控股(000950.SZ)披露控股子公司收購重慶長聖醫藥有限公司51%股權的進展,截至2021年1月12日,交易各方簽訂的《股權轉讓合同》的生效條件已達成,《股權轉讓合同》即日起生效,所附生效條件達成情況如下:
1、2020年12月11日,天聖製藥召開2020年第二次臨時股東大會,審議通過本次交易方案;
2、2021年1月12日,重藥股份依據國資管理接受非國有資產評估的相關要求完成了評估備案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.